Clinical

Articles

A new treatment arm of a phase 2 trial examining PDS0101 plus pembrolizumab in patients with HPV-related head and neck cancers will be opened to patients with immune checkpoint inhibitor–pretreated disease.

VERSATILE-002 Trial to Enroll Previously Treated HPV+ HNSCC Per Protocol Amendment 

Data investigating the predictive capabilities of high tumor mutation burden found it to be predictive of response to immune checkpoint blockade in some, but not all, types of cancers.

High Tumor Mutation Burden Predicts Response to Immune Checkpoint Blockade for Some Cancer Types

Compugen announced updated data surrounding the investigational therapeutic antibody, COM701, as monotherapy and in combination with nivolumab.

Updated Data Announced for Both COM701 Monotherapy and in Combination with Nivolumab

Recently reported results from the ongoing phase 1 TUNINTIL trial of the oncolytic virus TILT-123 show safety of this approach.

Oncolytic Virus TILT-123 Appears Safe, According to Preliminary Results of First-in-Human Trial 

Videos

Giorgio Trinchieri, MD, of the National Cancer Institute’s Center for Cancer Research joined CancerNetwork® to discuss enhancing the gut microbiome by way of fecal transplant for better immunotherapy responses.

Giorgio Trinchieri, MD, on Fecal Microbiota Transplant to Promote Immunotherapy Response

Bellicum Pharmaceuticals, the developer of BPX-601, can now begin enrolling patients to their phase 1/2 trial again without modification to the study protocol.

FDA Lifts Clinical Hold on Phase 1/2 Trial Evaluating BPX-601 for Metastatic Pancreatic, Prostate Cancer

Though the majority of immune-related adverse events (irAEs) can be managed with corticosteroids and other immunosuppressive treatments, life-threatening and sometimes fatal events have still been reported thus revealing a need to develop measures for effective management.

Strategies Proposed to Improve Management of Immune-Related Adverse Events

Idecabtagene vicleucel yielded a clinically meaningful improvements in the quality-of-life of triple-class exposed patients with relapsed/refractory multiple myeloma.

Ide-Cel Improves HRQoL in Triple-Class Exposed Relapsed/Refractory Myeloma

Experts discuss the case of a 56-year-old white man who presents with multiple immune-related adverse events

Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab

For those with early-stage melanoma, surgery may be the only treatment needed. However, when melanoma has spread beyond the skin, additional treatments before or after surgery may be necessary.

Immunotherapy | Topics